Publications

Pediatric Exclusivity Revenues for Cancer Drugs.

JAMA Pediatr
Sarpatwari A, Bendicksen L, Hawkins DS, Gore L, Bourgeois FT.

Biosimilar approval pathways: comparing the roles of five medicines regulators.

J Law Biosci
Knox RP, Desai V, Sarpatwari A

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020.

Drug Saf
Mahesri M, Sarpatwari A, Huybrechts KF, Lii J, Lee SB, Toyserkani GA, LaCivita C, Zhou EH, Dal Pan GJ, Kesselheim AS, Bykov K.

Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.

Pediatr Blood Cancer
Liu ITT, Wang J, Sarpatwari A, Kesselheim AS, Feldman WB.

Biosimilar Uptake In The US: Patient And Prescriber Factors.

Health Aff (Millwood)
Hong D, Kesselheim AS, Sarpatwari A, Rome BN

Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.

JAMA Netw Open
Feldman WB, Mahesri M, Sarpatwari A, Huybrechts KF, Zhu Y, Hwang CS, Lii J, Lee SB, Kattinakere Sreedhara S, Toyserkani GA, Zhou EH, Zendel L, LaCivita C, Manzo C, Dal Pan GJ, Kesselheim AS, Bykov K

Federal Trade Commission Actions on Prescription Drugs, 2000-2022.

JAMA
Daval CJR, Egilman AC, Sarpatwari A, Kesselheim AS.

Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label.

Ann Intern Med
Egilman AC, Kesselheim AS, Sarpatwari A, Rome BN.

Use of Artificial Intelligence in Drug Development.

JAMA Netw Open
Druedahl LC, Price WN, Minssen T, Sarpatwari A.

Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.

JAMA
Sarpatwari A, Kohli S, Tu SS, Kesselheim AS.

Improving Drug Supply Chain Security.

JAMA Health Forum
Kannarkat JT, Denham MW, Sarpatwari A.

Changes in Induced Medical and Procedural Abortion Rates in a Commercially Insured Population, 2018 to 2022 : An Interrupted Time-Series Analysis.

Ann Intern Med
Hwang CS, Kesselheim AS, Sarpatwari A, Huybrechts KF, Brill G, Rome BN.

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.

PLoS One
Sarpatwari A, Brown BL, McGraw SA, Dejene SZ, Abdurrob A, Kesselheim AS.

Public Returns on Public Investment: Moderna's Violation of the Social Contract.

J Law Med Ethics
Sarpatwari A.

INTRODUCTION: Promoting Drug and Vaccine Innovation and Managing High Prices: Introducing a Special Symposium.

J Law Med Ethics
Kesselheim A, Sarpatwari A, Rome B.